[Federal Register Volume 60, Number 165 (Friday, August 25, 1995)]
[Notices]
[Pages 44357-44358]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-21094]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 95N-0271]
Drug Export; Anzemet (Dolasetron Mesilate) Tablets 25 mg, 50 mg,
100 mg, 200 mg
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that
Marion Merrell Dow Inc., has filed an application requesting
conditional approval for the export of the human drug Anzemet
(dolasetron mesilate) Tablets to France for packaging and transshipment
to the United Kingdom.
ADDRESSES: Relevant information on this application may be directed to
the Dockets Management Branch (HFA-305), Food and Drug Administration,
Rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact
person identified below. Any future inquiries concerning the export of
[[Page 44358]]
human drugs under the Drug Export Amendments Act of 1986 should also be
directed to the contact person.
FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Center for Drug
Evaluation and Research, HFD-310 Food and Drug Administration, 7520
Standish Place, Rockville, MD 20855, 301-594-3150.
SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of
the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382)
provide that FDA may approve applications for the export of drugs that
are not currently approved in the United States. Section 802(b)(3)(B)
of the act sets forth the requirements that must be met in an
application for approval. Section 802(b)(3)(C) of the act requires that
the agency review the application within 30 days of its filing to
determine whether the requirements of section 802(b)(3)(B) have been
satisfied. Section 802(b)(3)(A) of the act requires that the agency
publish a notice in the Federal Register within 10 days of the filing
of an application for export to facilitate public participation in its
review of the application. To meet this requirement, the agency is
providing notice that Marion Merrell Dow, Inc., Marion Park Drive, P.O.
Box 9627, Kansas City, Missouri 64134-0627, has filed an application
requesting conditional approval for the export of the human drug
Anzemet (dolasetron mesilate) Tablets to France for packaging and
transshipment to the United Kingdom. Anzemet is used for the treatment
of nausea and vomiting induced by cancer chemotherapy, radiotherapy and
post-operative nausea and vomiting. The application was received and
filed in the Center for Drug Evaluation and Research on August 8, 1995,
which shall be considered the filing date for purposes of the act.
Interested persons may submit relevant information on the
application to the Dockets Management Branch (address above) in two
copies (except that individuals may submit single copies) and
identified with the docket number found in brackets in the heading of
this document. These submissions may be seen in the Dockets Management
Branch between 9 a.m. and 4 p.m., Monday through Friday.
The agency encourages any person who submits relevant information
on the application to do so by September 5, 1995, and to provide an
additional copy of the submission directly to the contact person
identified above, to facilitate consideration of the information during
the 30-day review period.
This notice is issued under the Federal Food, Drug, and Cosmetic
Act (sec.and Drugs (21 CFR 5.10) and redelegated to the Center for Drug
Evaluation and 802 (21 U.S.C. 382)) and under authority delegated to
the Commissioner of Food Research (21 CFR 5.44).
Dated: August 14, 1995.
Betty L. Jones,
Deputy Director, Office of Compliance, Center for Drug Evaluation and
Research.
[FR Doc. 95-21094 Filed 8-24-95; 8:45 am]
BILLING CODE 4160-01-F
